Skip to main content

Table 2 Comparison of the toleration, timely titration, dose optimization and overall ACEI treatment optimization during different periods of titration among heart failure patients taking ACEI at the cardiac clinic of Ayder Comprehensive Specialized Hospital, 2016

From: Treatment optimization of angiotensin converting enzyme inhibitors and associated factors in Ayder Comprehensive Specialized Hospital: a cross-sectional study

 

First titration

Second titration

Third titration

Fourth and beyond titration

Current titration

Overall status

Was the ACEI tolerated during?

 Yesa, n (%)

54 (88.5)

55 (90.2)

51 (83.6)

54 (88.5)

53 (86.9)

49 (80.3)

 No, n (%)

7 (11.5)

6 (9.8)

10 (16.4)

7 (11.5)

8 (13.1)

12 (19.7)

Was the ACEI timely titrated during?

 Yes, n (%)

26 (42.6)

26 (42.6)

27 (44.3)

24 (39.3)

23 (37.7)

7 (11.5)

 No, n (%)

35 (57.4)

35 (57.4)

34 (55.7)

34 (55.7)

38 (62.3)

54 (88.5)

Was the dose of ACEI optimized during?

 Yes, n (%)

31 (50.8)

35 (57.4)

27 (44.3)

29 (49.2)

30 (49.2)

17 (27.9)

 No, n (%)

30 (49.2)

26 (42.6)

34 (55.7)

32 (52.5)

31 (50.8)

44 (72.1)

Was the overall ACEI treatment optimized?

 Yes, n (%)

12 (19.7)

15 (24.6)

10 (16.4)

12 (19.7)

12 (19.7)

2 (3.3)

 No, n (%)

49 (80.3)

46 (75.4)

51 (83.6)

49 (80.3)

49 (80.3)

59 (96.7)

  1. ACEI, angiotensin converting enzyme inhibitor
  2. aThe cut off point for “yes” was 5 and for “no” was 0–4, considering the five titration periods from first up to the current